Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers.
Dong B, Xu JY, Huang Y, Guo J, Dong Q, Wang Y, Li N, Liu Q, Zhang M, Pan Q, Wang H, Jiang J, Chen B, Shen D, Ma Y, Zhai L, Zhang J, Li J, Xue W, Tan M, Qin J.
Dong B, et al. Among authors: wang h, wang y.
Nat Cancer. 2024 Sep;5(9):1427-1447. doi: 10.1038/s43018-024-00820-2. Epub 2024 Sep 6.
Nat Cancer. 2024.
PMID: 39242942